Cabazitaxel With BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer Following Treatment With Docetaxel: Phase II Study With Safety Lead-in Cohort
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 17 Feb 2016
Price : $35 *
At a glance
- Drugs Buparlisib (Primary) ; Cabazitaxel
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Jan 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 28 Apr 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 09 Apr 2014 Planned initiation date changed from 1 Mar 2014 to 1 May 2014 as reported by ClinicalTrials.gov.